The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 12, 2019

Filed:

May. 08, 2015
Applicant:

Nogra Pharma Limited, Dublin, IE;

Inventor:

Giovanni Monteleone, Grottaferrata, IT;

Assignee:

Nogra Pharma Limited, Dublin, IE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); C12N 15/113 (2010.01); A61P 1/00 (2006.01); A61K 31/7125 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); A61K 31/7125 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); C12N 15/113 (2013.01); G01N 33/6863 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); G01N 2333/4737 (2013.01); G01N 2800/065 (2013.01); G01N 2800/52 (2013.01);
Abstract

Methods of treating a subject with IBD with an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, to reduce CRP levels are disclosed. Methods of treating and managing IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, based on CRP levels are also disclosed. Also disclosed are methods of determining whether a subject with IBD is responsive or likely to be responsive to treatment an anti-SMAD7 therapy. Reduction of CRP levels may correlated with IBD remission or decreases in CDAI score. The present invention also relates to treatment of IBD using an anti-SMAD7 therapy (e.g., an antisense oligonucleotide) in combination with an additional agent. The invention also features related pharmaceutical compositions and kits.


Find Patent Forward Citations

Loading…